Franklin W. Huang

San Francisco VA Medical Center

Full Professor(heuristic)

Prostate Cancer Treatment and Research · Pulmonary and Respiratory Medicine

h-index35

i10-index64

Publications320

Citations22,889

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 71

Supplemental Table 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplemental Table 4 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplementary File 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplemental Figure 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplemental Figure 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplemental Figure 8 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplemental Figure 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplemental Figure 6 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplemental Table 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplementary File 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplemental Figure 7 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplemental Table 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplementary File 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplemental Figure 4 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplemental Figure 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplemental Table 6 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Supplemental Table 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2026-06-17
Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer
npj Precision Oncology · 2026-04-28
Clinical Implications of the Duffy-Null Genotype in Patients on Azathioprine or Methotrexate in the All of Us Cohort
The Journal of Applied Laboratory Medicine · 2026-04-14 · 1 citations
Abstract 2667: TM4SF1 as a novel tumor-associated antigen in biliary tract cancers targetable by immune effector cell therapy
Cancer Research · 2026-04-03

Open author page on OpenAlex →